Contact and support
Need help, have a question, or want to contact the ResearchHub team?
© 2026 ResearchHub. Built for responsible scholarly connection.
Privacy-aware community infrastructureResearch graph
References from Immunogenicity and safety of a single dose of adjuvanted RSVPreF3 vaccine in adults ≥60 years of age in China: results from a phase 3 immunobridging trial. Local targets link to admitted publications; unresolved targets remain external evidence.
Global, regional, and national disease burden estimates of acute lower respiratory infections due to respiratory syncytial virus in children younger than 5 years in 2019: a systematic analysis
10.1016/s0140-6736(22)00478-0 · 2022 · External reference
Respiratory syncytial virus disease burden in adults aged 60 years and older in high-income countries: A systematic literature review and meta-analysis
10.1111/irv.13031 · 2023 · External reference
Global disease burden estimates of respiratory syncytial virus-associated acute respiratory infection in older adults in 2015: A systematic review and meta-analysis
10.1093/infdis/jiz059 · 2020 · External reference
Disease burden estimates of respiratory syncytial virus related acute respiratory infections in adults with comorbidity: A systematic review and meta-analysis
10.1093/infdis/jiab040 · 2022 · External reference
Etiological and epidemiological features of acute respiratory infections in China
10.1038/s41467-021-25120-6 · 2021 · External reference
A promise fulfilled: Updates on respiratory syncytial virus vaccines and monoclonal antibodies
10.1016/j.jaci.2025.10.023 · 2026 · External reference
RSV vaccine effectiveness against hospitalization among US adults 60 years and older
10.1001/jama.2024.15775 · 2024 · External reference
RSV vaccine effectiveness against hospitalization among US adults aged 60 years or older during 2 seasons
10.1001/jama.2025.15896 · 2025 · External reference
Associations of altruistic factors and perceptions with intention to receive respiratory syncytial virus (RSV) vaccination among older adults in China
10.1080/21645515.2025.2567705 · 2025 · External reference
Respiratory syncytial virus prefusion F protein vaccine in older adults
10.1056/nejmoa2209604 · 2023 · External reference
Efficacy and safety of respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) in older adults over 2 RSV seasons
10.1093/cid/ciae010 · 2024 · External reference
Efficacy, safety, and immunogenicity of the AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine (RSVPreF3 OA) in older adults over three respiratory syncytial virus seasons (AReSVi-006): a multicentre, randomised, observer-blinded, placebo-controlled, phase 3 trial
10.1016/s2213-2600(25)00048-7 · 2025 · External reference
Expansion of the 1st WHO international standard for antiserum to respiratory syncytial virus to include neutralisation titres against RSV subtype B: An international collaborative study
10.1016/j.vaccine.2019.10.095 · 2020 · External reference
Establishment of the first WHO International Standard for antiserum to respiratory syncytial virus: Report of an international collaborative study
10.1016/j.vaccine.2018.10.087 · 2018 · External reference
Unresolved reference
External reference
Unresolved reference
External reference
Comparative analysis of two rates
10.1002/sim.4780040211 · 1985 · External reference
The use of confidence or fiducial limits illustrated in the case of the binomial
10.2307/2331986 · 1934 · External reference
Noninferior immunogenicity and consistent safety of respiratory syncytial virus prefusion F protein vaccine in adults 50–59 years compared to ≥60 years of age
10.1093/cid/ciae364 · 2024 · External reference
Immunogenicity and safety following 1 dose of AS01E-adjuvanted respiratory syncytial virus prefusion F protein vaccine in older adults: A phase 3 trial
10.1093/infdis/jiad546 · 2024 · External reference
Factors that influence the immune response to vaccination
10.1128/cmr.00084-18 · 2019 · External reference
Frailty impacts immune responses to Moderna COVID-19 mRNA vaccine in older adults
10.1186/s12979-023-00327-x · 2023 · External reference
Robust and consistent immune response of the adjuvanted respiratory syncytial virus (RSV) prefusion F protein vaccine (RSVPreF3 OA) across different age ranges and frailty status in older adults
10.1093/ofid/ofae631.077 · 2025 · External reference
Estimated efficacy of the adjuvanted RSVPreF3 vaccine against diverse and worldwide predominant RSV strains, irrespective of RSV F protein variation: Results of a post-hoc analysis from the AReSVi-006 trial
10.1016/j.ebiom.2026.106296 · 2026 · External reference
Immunogenicity, reactogenicity, and safety of AS01E-adjuvanted RSV prefusion F protein-based candidate vaccine (RSVPreF3 OA) when co-administered with a seasonal quadrivalent influenza vaccine in older adults: Results of a phase 3, open-label, randomized controlled trial
10.1093/cid/ciad786 · 2024 · External reference
Negative population growth and population ageing in China
10.1007/s42379-023-00138-z · 2023 · External reference
Unresolved reference
External reference
Systematic literature review of risk factors for poor outcomes among adults with respiratory syncytial virus infection in high-income countries
10.1093/ofid/ofad513 · 2023 · External reference
Burden of respiratory syncytial virus disease in adults with asthma and chronic obstructive pulmonary disease: A systematic literature review
10.1007/s11882-025-01194-w · 2025 · External reference
Burden and severity of respiratory syncytial virus infection in adults with cardiovascular diseases: A systematic literature review
10.1016/j.pcad.2025.06.010 · 2025 · External reference
